Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07050771 · ClinicalTrials.gov registry record · Phase 2
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
A Phase 2 study of Bladder Cancer and Kidney Cancers, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 1
- Study location
NCT07050771: Recruiting Phase 2 study of Bladder Cancer and Kidney Cancers, sponsored by The Methodist Hospital Research Institute.
NCT07050771 is a Phase 2 study of Bladder Cancer and Kidney Cancers that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 148 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07050771, a Phase 2 study of Bladder Cancer and Kidney Cancers, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail patients with probable/proven pancreaticobiliary, ovarian, kidney, or bladder cancer prior to elective major cancer surgery (EMCS).
Primary Outcome
Percentage of patients alive without any postoperative complications (as defined by the American College of Surgeons National Surgical Quality Improvement Program {ACS NSQIP\]) in each study arm.
Conditions Studied
Interventions
- OTHER Comprehensive multimodal prehabilitation (CMMP)
Study Locations (1)
Texas
- Houston Methodist Neal Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2025-08-14 |
| Est. Completion | 2027-10-01 |
| Phase | Phase 2 |
What NCT07050771 shows while recruiting
NCT07050771 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 1 intervention - of which Comprehensive multimodal prehabilitation (CMMP) is the first listed.
NCT07050771 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07050771 about?
NCT07050771 is a clinical study titled "Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery". In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail patients with probable/proven pancreaticobiliary, ovarian, kidney, or bl...
What is the current status of trial NCT07050771?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2025-08-14. Estimated completion is 2027-10-01.
What conditions does trial NCT07050771 study?
This clinical trial studies the following conditions: Bladder Cancer, Kidney Cancers, Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa).
What interventions are being tested in trial NCT07050771?
The interventions under investigation include: Comprehensive multimodal prehabilitation (CMMP) (OTHER).
Who is sponsoring clinical trial NCT07050771?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07050771 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07050771's enrollment target sits among peer trials
148 69th of 175 higher than 107 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
-
Intravenous Ascorbate Plus Gemcitabine/Carboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI